Medtronic PLC (MDT) - Total Assets
Based on the latest financial reports, Medtronic PLC (MDT) holds total assets worth $93.03 Billion USD as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medtronic PLC - Total Assets Trend (1986–2026)
This chart illustrates how Medtronic PLC's total assets have evolved over time, based on quarterly financial data. Also see how much is Medtronic PLC worth for the company's overall valuation and market capitalisation.
Medtronic PLC - Asset Composition Analysis
Current Asset Composition (April 2026)
Medtronic PLC's total assets of $93.03 Billion consist of 26.6% current assets and 73.4% non-current assets. Review how much debt does Medtronic PLC carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $6.64 Billion | 7.1% |
| Inventory | $5.95 Billion | 6.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.15 Billion | 10.9% |
| Goodwill | $42.59 Billion | 45.8% |
Asset Composition Trend (1986–2026)
This chart illustrates how Medtronic PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Medtronic PLC for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medtronic PLC's current assets represent 26.6% of total assets in 2026, a decrease from 67.3% in 1986.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2026, down from 25.7% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 9.0% in 1986.
- Asset Diversification: The largest asset category is goodwill at 45.8% of total assets.
Medtronic PLC Competitors by Total Assets
Key competitors of Medtronic PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A
SHE:300760
|
China | CN¥59.27 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
Brainsway Ltd
NASDAQ:BWAY
|
USA | $121.97 Million |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
USA | $272.12 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
Medtronic PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 1.85 | 2.89 |
| Quick Ratio | 1.62 | 1.42 | 2.34 |
| Cash Ratio | 0.00 | 0.17 | 0.39 |
| Working Capital | $13.13 Billion | $10.94 Billion | $14.67 Billion |
Medtronic PLC - Advanced Valuation Insights
This section examines the relationship between Medtronic PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | $93.03 Billion |
| Market Capitalization | $109.30 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Medtronic PLC's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Medtronic PLC's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medtronic PLC (1986–2026)
The table below shows the annual total assets of Medtronic PLC from 1986 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-04-30 | $93.03 Billion | +1.47% |
| 2025-04-30 | $91.68 Billion | +1.89% |
| 2024-04-30 | $89.98 Billion | -1.06% |
| 2023-04-30 | $90.95 Billion | -0.04% |
| 2022-04-30 | $90.98 Billion | -2.26% |
| 2021-04-30 | $93.08 Billion | +2.64% |
| 2020-04-30 | $90.69 Billion | +1.11% |
| 2019-04-30 | $89.69 Billion | -1.86% |
| 2018-04-30 | $91.39 Billion | -8.44% |
| 2017-04-30 | $99.82 Billion | +0.27% |
| 2016-04-30 | $99.55 Billion | -6.69% |
| 2015-04-30 | $106.69 Billion | +181.17% |
| 2014-04-30 | $37.94 Billion | +9.05% |
| 2013-04-30 | $34.79 Billion | +5.17% |
| 2012-04-30 | $33.08 Billion | +8.74% |
| 2011-04-30 | $30.42 Billion | +8.31% |
| 2010-04-30 | $28.09 Billion | +18.72% |
| 2009-04-30 | $23.66 Billion | +6.59% |
| 2008-04-30 | $22.20 Billion | +13.77% |
| 2007-04-30 | $19.51 Billion | -0.78% |
| 2006-04-30 | $19.66 Billion | +18.34% |
| 2005-04-30 | $16.62 Billion | +17.76% |
| 2004-04-30 | $14.11 Billion | +14.53% |
| 2003-04-30 | $12.32 Billion | +12.99% |
| 2002-04-30 | $10.90 Billion | +54.92% |
| 2001-04-30 | $7.04 Billion | +24.16% |
| 2000-04-30 | $5.67 Billion | +16.41% |
| 1999-04-30 | $4.87 Billion | +75.53% |
| 1998-04-30 | $2.77 Billion | +15.17% |
| 1997-04-30 | $2.41 Billion | -3.76% |
| 1996-04-30 | $2.50 Billion | +28.59% |
| 1995-04-30 | $1.95 Billion | +19.92% |
| 1994-04-30 | $1.62 Billion | +26.18% |
| 1993-04-30 | $1.29 Billion | +10.57% |
| 1992-04-30 | $1.16 Billion | +13.61% |
| 1991-04-30 | $1.02 Billion | +19.57% |
| 1990-04-30 | $856.50 Million | +12.76% |
| 1989-04-30 | $759.60 Million | +18.54% |
| 1988-04-30 | $640.80 Million | +14.49% |
| 1987-04-30 | $559.70 Million | +6.12% |
| 1986-04-30 | $527.40 Million | -- |
About Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardiovert… Read more